Evidence map›Paper›PMID 29657854›Full record

ArticleJournal of translational science2018

Targeted drug discovery and development, from molecular signaling to the global market: an educational program at New York University, 5-year metrics.

Gloria Lee, Joseph Plaksin, Ravichandran Ramasamy, Gabrielle Gold-von Simson

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gloria LeeT35 NIDDK Honors Trainee, Clinical and Translational Science Institute, New York University School of Medicine, NY, NY, USA.
Joseph PlaksinDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Ravichandran RamasamyDepartments of Medicine, Biochemistry and Molecular Pharmacology, co-PI NIDDK R25, New York University School of Medicine, New York, NY, USA.
Gabrielle Gold-von SimsonDepartment of Pediatrics, PI NIDDK R25, New York University School of Medicine, New York, NY, USA.
Duke University · US

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
VASCULAR AND MONOCYTE DYSFUNCTION IN WOUND REPAIRP01HL060901 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI YAN, SHI FANG · 1999 to 2017
$20.2M
Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL, HOCHMAN, JUDITH S · 2012 to 2014
$16.8M
Targeting RAGE-mDia1 in Diabetic Complications: Mechanisms and TherapeuticsR24DK103032 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN, SCHMIDT, ANN MARIE · 2014 to 2018
$4.2M
RAGE/mDia1, Macrophage Trafficking and Inflammation in High Fat FeedingR01DK109675 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN, SCHMIDT, ANN MARIE · 2016 to 2020
$2.6M
RAGE/mDia1, Macrophage Trafficking and Inflammation in Regression of Diabetic AtherosclerosisR01HL132516 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN, SCHMIDT, ANN MARIE · 2017 to 2020
$2.5M
SHORT-TERM TRAINING: STUDENTS IN HEALTH PROFESSIONAL SCHT35DK007421 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN · 1985 to 2023
$2.5M
Fatty Acids: Ischemic Protection and RepairR01HL135987 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GOLDBERG, IRA J, RAMASAMY, RAVICHANDRAN · 2017 to 2020
$2.4M
A New Era of Targeted Drug Discovery and the Path of Development: From MolecularR25DK092170 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GOLD-VON SIMSON, GABRIELLE, RAMASAMY, RAVICHANDRAN · 2012 to 2016
$469k
NCATS NIH HHS UL1 TR001445NHLBI NIH HHS P01 HL060901NHLBI NIH HHS R01 HL132516NHLBI NIH HHS R01 HL135987NIDDK NIH HHS R01 DK109675NIDDK NIH HHS R24 DK103032NIDDK NIH HHS R25 DK092170NIDDK NIH HHS T35 DK007421
6 · The paper itself

Abstract

Drug discovery and development (DDD) is a collaborative, dynamic process of great interest to researchers, but an area where there is a lack of formal training. The Drug Development Educational Program (DDEP) at New York University was created in 2012 to stimulate an improved, multidisciplinary DDD workforce by educating early stage scientists as well as a variety of other like-minded students. The first course of the program emphasizes post-compounding aspects of DDD; the second course focuses on molecular signaling pathways. In five years, 196 students (candidates for PhD, MD, Master's degree, and post-doctoral MD/PhD) from different schools (Medicine, Biomedical Sciences, Dentistry, Engineering, Business, and Education) completed the course(s). Pre/post surveys demonstrate knowledge gain across all course topics. 26 students were granted career development awards (73% women, 23% underrepresented minorities). Some graduates of their respective degree-granting/post-doctoral programs embarked on DDD related careers. This program serves as a framework for other academic institutions to develop compatible programs designed to train a more informed DDD workforce.

Indexed as

careerdrug developmentdrug discoveryeducationgraduate studenttranslation

Identifiers

PMID29657854
PMCPMC5898375
OpenAlexW2796808708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.